Equity Profile

PODD

Insulet Corporation

Health CareHealth Care Equipment$11.2B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insulet Corporation operates in the health care sector, focusing on innovative medical devices for diabetes management, particularly its Omnipod insulin delivery system. As a leader in health care equipment, Insulet plays a crucial role in improving patient outcomes and enhancing the quality of life for those with diabetes.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is allocated to each share of stock.

N/A

Revenue Growth

Revenue growth indicates how well the company is expanding its market share and product adoption, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1-2026, Insulet reported an EPS of $1.42, exceeding expectations by 24.78%. However, the stock declined by 9.70% the following day, indicating market skepticism despite the earnings beat.

Management Promises & Guidance

Focus on expanding the Omnipod product line.
Commitment to improving operational efficiency.
Plans to enhance customer support and education for users.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Insulet's upcoming earnings, especially given its history of beating EPS estimates. However, the lack of revenue guidance raises concerns about future growth.

Bull Case

If Insulet continues its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could trigger a sell-off, especially given the recent stock price decline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Insulet's history of beating EPS estimates, the actual EPS will be critical in determining market sentiment and stock movement.

How is the company addressing competition in the diabetes management market?

Understanding Insulet's competitive strategy will provide insights into its growth potential and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Insulet's ability to capture market share in the diabetes management sector, especially with its innovative product offerings.

Supporting Evidence

Insulet has consistently beaten EPS estimates, indicating stronger-than-expected demand.

The options market is pricing a significant move, suggesting traders anticipate volatility that may not align with consensus expectations.

Key Risk

If the actual EPS falls below $1.30, it could challenge the current optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Insulet's ability to maintain its growth trajectory amidst increasing competition in the diabetes management space.

Bull Confirmed If

An EPS of $1.50 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.30 would raise concerns about market share and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests the stock could rise by around 1.9%, confirming strong demand and operational success.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see muted movement as investors weigh future growth prospects.

Miss

A miss could lead to a decline of about 1.1%, reflecting investor disappointment and concerns over competitive pressures.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the expansion of the Omnipod product line.
2Details on customer feedback and adoption rates for recent product launches.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on competition in the diabetes management market.
5Any commentary on future revenue guidance or market trends.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is allocated to each share of stock.

N/A

Revenue Growth

Revenue growth indicates how well the company is expanding its market share and product adoption, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1-2026, Insulet reported an EPS of $1.42, exceeding expectations by 24.78%. However, the stock declined by 9.70% the following day, indicating market skepticism despite the earnings beat.

Management Promises & Guidance

Focus on expanding the Omnipod product line.
Commitment to improving operational efficiency.
Plans to enhance customer support and education for users.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Insulet's upcoming earnings, especially given its history of beating EPS estimates. However, the lack of revenue guidance raises concerns about future growth.

Bull Case

If Insulet continues its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could trigger a sell-off, especially given the recent stock price decline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Insulet's history of beating EPS estimates, the actual EPS will be critical in determining market sentiment and stock movement.

How is the company addressing competition in the diabetes management market?

Understanding Insulet's competitive strategy will provide insights into its growth potential and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Insulet's ability to capture market share in the diabetes management sector, especially with its innovative product offerings.

Supporting Evidence

Insulet has consistently beaten EPS estimates, indicating stronger-than-expected demand.

The options market is pricing a significant move, suggesting traders anticipate volatility that may not align with consensus expectations.

Key Risk

If the actual EPS falls below $1.30, it could challenge the current optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Insulet's ability to maintain its growth trajectory amidst increasing competition in the diabetes management space.

Bull Confirmed If

An EPS of $1.50 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.30 would raise concerns about market share and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests the stock could rise by around 1.9%, confirming strong demand and operational success.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may see muted movement as investors weigh future growth prospects.

Miss

A miss could lead to a decline of about 1.1%, reflecting investor disappointment and concerns over competitive pressures.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the expansion of the Omnipod product line.
2Details on customer feedback and adoption rates for recent product launches.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on competition in the diabetes management market.
5Any commentary on future revenue guidance or market trends.